SUB ARACHNOID HEMORRHAGE: EVALUATION AND MEDICAL MANAGEMENT
INTRODUCTION

- SAH refers to extravasation of blood into the subarachnoid space between the pial and arachnoid membranes due to some pathological process.
- Overall incidence reported between 2-49 cases/1 lakh / yr
- 11 cases/ lakh / yr for aneurysmal SAH
- Comprises 6-8% of all strokes
- Associated with an annual cost of $1.75 billion (USA)
INTRODUCTION

- M.C. cause of spontaneous SAH is from a ruptured intracranial aneurysm
- An estimated 10-15% of patients die before reaching the hospital
- Advances in the management of subarachnoid hemorrhage have resulted in a relative reduction in mortality rate that exceeds 25%. However, more than one third of survivors have major neurological deficits
RELEVANT ANATOMY

- "Arachnoid" comes from the Greek "arachne" meaning spiderweb + "eidos" meaning resemblance = spider-web-like
- Subarachnoid space is the interval between the arachnoid membrane and pia mater
- It is occupied by a spongy tissue consisting of trabeculae and intercommunicating channels in which the CSF is contained
- The subarachnoid space extends from the basal cisterns surrounding the brainstem superiorly to S2 level inferiorly. The meninges continue caudal from this point fused as the filum terminale
- Subarachnoid space is the location of the interface between the vascular tissue and CSF
HISTORICAL PERSPECTIVE

- Ancient Greek, Egyptian & Arabic literature all have references to intracranial aneurysm & SAH
- Dandy performed the first successful clipping of an aneurysm in 1937, using a vascular clip designed by Harvey Cushing
- Angiographic vasospasm first described by Ecker & Riemen(1951)
- Clinical vasospasm described by Pool, Maspes and Marini et al in 1960s
HISTORICAL PERSPECTIVE

- Endovascular therapy for the treatment of intracranial aneurysms was pioneered in the mid 1970s by Serbinenko at the Moscow Institute of Neurosurgery.


- In 1983 Allen and co-workers published first controlled trial of nimodipine in SAH.

- In 1990 Guglielmi et al, at the University of California Los Angeles (UCLA) Medical Center developed the Guglielmi detachable coil system (GDC- platinum coil).
ETIOLOGY OF SAH

- **TRAUMA** – Most common cause

**SPONTANEOUS SAH**-
- **ANEURYSM** – 70 to 80% of spontaneous SAH
- **AVM**- 4-5% cases
- **INFECTIONS**
- **NEOPLASIA**
- **INFLAMMATORY** (*vasculitis*)
- **COAGULATION DISORDER**
- **DURAL SINUS THROMBOSIS**
- **PRETRUNCAL NON ANERYSMAL SAH**
- **CEREBRAL ARTERY DISSECTION**
- **RUPTURE OF INFUNDIBULUM**
- **PITUITARY APOPLEXY**
- **SICKLE CELL DISEASE**
- **DRUGS and TOXINS** (cocaine abuse, amphetamine, MAO inhibitor, alcohol, CO, nicotine, quinine, snake venom)

- **IDIOPATHIC** (SAH of unknown etiology, 14-22%)
RISK FACTORS

- Smoking and hypertension appears to be a significant risk factor, as does heavy alcohol consumption.
- The risk of AVM rupture is greater during pregnancy.

The following are doubtful risk factors for SAH:

- Use of oral contraceptives
- Hormone replacement therapy
- Hypercholesterolemia
- Increasing age
PATHOPHYSIOLOGY

- Blood extravasates under pressure into the subarachnoid space and quickly spreads through the CSF around the brain & spinal cord
- Blood released under high pressure may directly cause damage to local tissues
- Blood extravasation causes a global increase in intracranial pressure
- Meningeal irritation occurs
DEMOGRAPHY

- Race- Blacks have a higher risk for SAH than whites (2.1:1)

- Sex- Incidence of aneurysmal SAH is higher in women than in men

- Age- Mean age of those experiencing subarachnoid hemorrhage is 50 years

- Clusters of familial occurrence, such as in Finland where the incidence of familial cerebral aneurysm is 10%
CLINICAL PRESENTATION

Headache –
- Present in 97% cases
- A sudden onset of severe headache, often described as the "worst headache of my life"
- Prodromal (warning) headache(s) from minor blood leakage (sentinel headache) is reported in 30-60% of SAH
- Sentinel headaches may occur a few hours to a few months before the rupture, with a reported median of 2 weeks prior to diagnosis of SAH. It may be due to sentinel leaks, mass effect of aneurysm expansion or emboli
- Minor leaks are not a feature of AVM
CLINICAL PRESENTATION

- Nausea and/or vomiting
- Symptoms of meningeal irritation (e.g.- neck stiffness, Kernig’s/Brudzinski’s sign, low back pain, bilateral leg pain): >75% of cases of SAH, but many take several (6-24 hrs) hours to develop
- Photophobia and visual changes
- A sudden LOC occurs at the ictus in 45% of patients, often transient; but in 10% of patients are comatose for several days
- Coma in SAH may be d/t raised ICP, ICH, HCP, seizure, low CBF
- Seizures during the acute phase of SAH occur in 10-25% of patients
CLINICAL PRESENTATION

- Focal neurologic abnormalities (25%) : hemiparesis, aphasia, hemineglect, cranial nerve palsies, memory loss

- **Ocular hemorrhages** (20-40%) : sub hyaloid pre-retinal hemorrhages / intra-retinal hemorrhage surrounding fovea / intra-vitreous hemorrhage (*Terson syndrome*). D/t compression of CRV / retinochoroidal anastomosis by raised, leading to venous disruption

- BP elevation is observed in about 50% of patients. BP often becomes labile as ICP increases

- Temperature elevation, secondary to chemical meningitis from subarachnoid blood products, is common after the fourth day following bleeding

- Tachycardia often is present for several days after SAH
SAH GRADING

Hunt and Hess grading system
- Grade 1 - Asymptomatic or mild headache
- Grade 2 - Moderate-to-severe headache, nuchal rigidity, and cranial nerve palsy
- Grade 3 - Mild alteration in mental status (confusion, lethargy), mild focal neurological deficit
- Grade 4 - Stupor and/or hemi paresis
- Grade 5 - Comatose and/or decerebrate rigidity

Modified classification-
- Grade 0 – Unruptured aneurysm
- Grade 1a – no acute meningeal reaction but with fixed neuro deficit

* Add one grade for HTN/DM/COPD/Severe Atherosclerosis/ angiographic vasospasm
SAH GRADING

WFNS scale
- Grade 0 – Intact aneurysm
- Grade 1 - GCS of 15, major focal deficit absent
- Grade 2 - GCS of 13-14, major focal deficit absent
- Grade 3 - GCS of 13-14, major focal deficit present
- Grade 4 - GCS of 7-12, major focal deficit absent or present
- Grade 5 - GCS of 3-6, major focal deficit absent or present

* Major focal deficit – aphasia/hemiparesis/hemiplegia
SAH GRADING

BOTTERELL GRADING:

- Grade 1 – conscious with or without signs of blood in subarachnoid space
- Grade 2 – drowsy without significant neurological deficit
- Grade 3 - drowsy with neurological deficit and probably ICH
- Grade 4 - significant neurological deficit, deteriorating because of large ICH or older patients with less severe deficit but pre-existing cerebrovascular disease
- Grade 5 – moribund with failing vital centers and extensor rigidity
SAH GRADING

Fischer scale (based on CT scan)

- Group 1 - No blood detected
- Group 2 - Diffuse deposition of subarachnoid blood and no layers of blood greater than 1 mm
- Group 3 - Localized clots and/or vertical layers of blood 1 mm or greater in thickness
- Group 4 - Diffuse or no subarachnoid blood, but intracerebral or intraventricular clots are present
SAH GRADING

- The Hunt & Hess and the WFNS grading systems have been shown to correlate with patient outcome.
- Fischer classification has been used successfully to predict the likelihood of symptomatic cerebral vasospasm.
- Admission H&H Gr 1 and 2: mortality is 20% & the major cause is rebleed (international cooperative aneurysm study)
WORK UP

- CBC count - For evaluation of possible infection or hematologic abnormality

- Prothrombin time (PT) and activated partial thromboplastin time (aPTT) - For evaluation of possible coagulopathy

- Serum electrolytes - To establish a baseline for detection of future complications

- Blood grouping

- Cardiac enzymes - For evaluation of possible myocardial ischemia

- Arterial blood gas (ABG) - Assessment is necessary in cases with pulmonary compromise
**WORK UP**

**CT scan:**
- The diagnosis of SAH usually depends on a high index of clinical suspicion combined with radiographic confirmation via NCCT. The sensitivity decreases with respect to increased time from ictus. CT scan has a sensitivity of 95% within the first 48 hours of the ictus; 80% at 72 hours and 50% at 1 week.
WORK UP (CT SCAN CONTD...)

- CT scan findings may be falsely negative in patients with small hemorrhages and in patients with severe anemia.

- In general, blood localized to the basal cisterns, the sylvian fissure, or the intrahemispheric fissure indicates rupture of a saccular aneurysm. Blood found lying over the convexities or within the superficial parenchyma of the brain often is indicative of AVM or mycotic aneurysm rupture.

- A.Com aneurysm rupture often a/w ant. interhemispheric fissure bleed, MCA/ PCom aneurysm rupture are a/w sylvian fissure bleed and IVH (3 & 4\textsuperscript{TH} ventricular) usually suggest PICA/ VA aneurysm rupture.

- CT also helpful to rule out HCP.

- CECT head may reveal AVM.
LUMBAR PUNCTURE-

- Most sensitive test for SAH (Caution: lowering CSF pressure may precipitate rebleeding)

- CT scan should be performed before LP to exclude significant intracranial ME, obstructive HCP or obvious intracranial hematoma

- Findings often are negative within 2 hours of the ictus & is most sensitive 12 hours after the bleed

- SAH can be distinguished from traumatic LP

- Xanthochromia appear until 2-4 hours after the ictus, is approx 100% present 12 hours after the bleed and remains for approximately 2 weeks. Xanthochromia is present 3 weeks after the bleed in 70% of patients, and it is still detectable at 4 weeks in 40% of patients, better appreciated by spectrophotometry

- RBC count usually > 1,00000/c mm, higher protein level d/t blood break down product
WORK UP

CEREBRAL ANGIOGRAPHY (DSA)-

- Gold standard for evaluation of cerebral aneurysm (80-85% sensitivity)

- Useful in cases of diagnostic uncertainty (after CT and LP)

- Can provide surgical information in the setting of SAH: Cerebrovascular anatomy, aneurysm location & source of bleeding, aneurysm size/shape/orientation of dome and neck, relation to the parent/perforating arteries

- If cerebral angiography findings are negative (10-20%) a repeat test should be performed 3-4 weeks later

- May be useful to evaluate for possible cerebral vasospasm
WORK UP

Magnetic resonance angiography (MRA):

- The role of MRA in the detection of SAH currently is under investigation. Given the current limitations of MRA (e.g., failure to detect PICA and ACom aneurysm in one series) most authors feel that the risk/benefit ratio still favors conventional angiography.

- Can detect aneurysms >3 mm with 86% sensitivity and is useful for monitoring the status of small, unruptured aneurysms.

- False +ve in approx. 16%.

- Can be used to evaluate the degree of intramural thrombus in giant aneurysms.

- Useful as a screening test in high risk patients including 1st degree relative of patients with IC aneurysm.
WORK UP

**CTA :**
- Reported to detect aneurysms larger than 3 mm with a sensitivity of 95% and 83% specificity. Provide sufficient anatomic detail esp relation to near by bony structure

**MRI :**
- Not sensitive for SAH within the first 48 hours, better after 4-7 days (met-Hb)
- Useful tool to diagnose cerebral / spinal AVMs causing SAH

**TCD :**
- TCD useful in the detection and monitoring of arterial vasospasm
WORK UP

ECG:
- Changes noted on ECG are attributed to myocardial ischemia and/or infarction caused by high levels of circulating catecholamines. Myocardial ischemia/infarction is present in 20% of SAH cases.

Chest radiograph:
- All patients with SAH should have a baseline chest radiograph to serve as a reference point for evaluation of possible pulmonary complications.

Echocardiogram:
- Evaluation of ventricular wall motion may be necessary in cases with suspected myocardial ischemia.
INITIAL MANAGEMENT CONCERNS -

- Rebleeding
- Hydrocephalus
- Delayed ischemic neurological deficit (DIND)
- Hyponatremia / hypovolemia
- DVT / Pulmonary embolism
- Seizures
- Determining the source of bleeding
Initial management of patients with SAH is stabilization. Assess the level of consciousness, airway, breathing and circulation (ABCs).

Endotracheal intubation should be performed for patients presenting with coma/depressed consciousness/inability to protect airway/increased ICP.

Vascular access should be obtained, including central and arterial lines.

Monitoring should include: Cardiac monitoring/Pulse oximetry/BP monitoring (arterial BP monitoring is indicated in high-grade SAH or when blood pressure is labile)/End-tidal carbon dioxide/Urine output via placement of a Foley catheter.
MANAGEMENT

Patients with signs of increased ICP

- Intubated and hyperventilated to achieve a PCO2 of 30-35 mm Hg. Excessive hyperventilation is avoided, which may potentiate vasospasm and ischemia

- Osmotic agents (e.g., mannitol), can decrease ICP dramatically (50% after 30 min post administration)

- Loop diuretics (e.g., furosemide) also can decrease ICP

- The use of IV steroids is controversial
MANAGEMENT

--Intraventricular catheter (ventriculostomy)- possible indication

○ Acute HCP or significant intraventricular blood. Allows drainage of CSF as well as ICP monitoring. May increase the risk of rebleed. Symptomatic improvement found in 30%, immediately

○ H&H grade >3 – some experts feel if there is some improvement with ventriculostomy, prognosis may be favourable

--Serial LP may be tried instead of ventriculostomy
MANAGEMENT

STANDARD ADMITTING ORDERS –

○ Admission in ICU with monitored bed

○ Vital parameter and neurological status check 1 hrly

○ Bed rest with head end elevated by 30 degree, low external stimulation

○ Nursing: strict I-O charting / daily weights / DVT pumps at LL / urinary catheterization / NG tube

○ IVF: Aggressive fluid therapy to head off cerebral salt wasting. NS + 20 meq KCl/L @ 2 ml/kg/hr

○ If Hct <40%, 500ml 5% albumin over 4 hrs, on admission

○ Avoid IM medication/ enema/ NSAID
**MANAGEMENT**

- **Prophylactic anticonvulsants**: 3% of SAH patients have seizure during acute illness. Use of prophylactic anticonvulsant is controversial, but most authorities recommend for 1 wk post op. Phenytoin is the usual agent used. Barbiturate is usually given for burst suppression in O.R.

- **Mild sedation** (propofol/midazolam/orazepam)

- **Analgesic**: fentanyl (lower ICP and doesn’t cause histamine release unlike morphine)

- **Steroid**: effect on brain edema is controversial, usually given prior to craniotomy

- **Stool softener** (bisacodyl) / anti-emetics (ondansetron) / H2 blocker or PPI or sucralfate
MANAGEMENT

ANTI-HYPERTENSIVE

- To maintain SBP 120-150 mm Hg for unclipped aneurysm
- The current recommendations advocate the use of antihypertensive agents when MAP exceeds 130 mm Hg
- Intravenous beta-blockers (labetolol) can be titrated easily and do not increase ICP. Beta-blockers are the agents of choice in patients without contraindications
- Hydralazine and calcium channel blockers have a fast onset and lead to relatively less increase in ICP than do nitrates
- Angiotensin-converting enzyme inhibitors have a relatively slow onset and are not first-line agents in the setting of acute SAH
MANAGEMENT

Calcium channel blocker: (Nimodipine / nicardipine/ nifedepine)

- Nimodipine 60 mg PO/NG q 4 hrs, initiated within 96hrs of SAH
- BRANT: British aneurysm nimodipine trial shown 22% vs. 33% incidence of cerebral infarction in compared to placebo
- CCB blocks the ‘slow channel’ of calcium influx which reduces the contraction of smooth muscles and may prevent vasospasm
- Possible beneficial effects are – improved RBC rheology / prevention of calcium entry in ischemic cells / anti platelet aggregation / dilatation of collateral lepto meningeal arteries
- Side effects are – systemic hypotension / renal failure / pulmonary edema
MANAGEMENT

- Oxygenation: Non intubated - Oxygen 2 Lit by ventimask
  Intubated - normocarbia & po2 > 100 mm Hg

- Monitoring of CVP q 4 hrs

- Following drugs are contraindicated for fear of impaired coagulation – aspirin / dextran / heparin / repeated administration of hetastarch

- For unsecured aneurysm, gentle volume expansion with slight hemodilution and mild elevation of BP may help reducing effects of vasospasm and cerebral salt wasting
MANAGEMENT

LABORATORY INVESTIGATIONS –

- ABG / electrolytes / CBC / PT – APTT on admission
- ABG / electrolytes / CBC / Hct daily
- Serum and urine osmolarity if UO is high/low
- C/S of respiratory secretion, urine, blood, CSF if fever or signs of infection
- CXR daily until stable
- TCD study
MANAGEMENT OF SPECIFIC PROBLEMS

FLUID AND ELECTROLYTE DISTURBANCES:

- MC electrolyte disturbances after SAH are hyponatremia (50%), hypernatremia, and hypokalemia.

- Hypokalemia should be corrected fast because it may predispose to cardiac arrhythmia.

- Mortality a/w hypernatremia is 42%, 15% for hyponatremia and 25% with DI.

- Most patients of SAH seem to become hypovolemic with low total blood volume even if maintenance fluid requirements are met. Causes may be d/t supine diuresis, pooling in peripheral vascular bed, inadequate erythropoiesis.

- Incidence of volume depletion increases with decreasing GCS.
HYponatremia following SAH

- Hypovolemia and hyponatremia frequently follow SAH as a result of natriuresis / diuresis

- MC cause is SIADH & CSWS (↑ANP/BNP/C-peptide)

- Hyponatremia may mimic or a/w DIND

- Risk factors: h/o DM, CHF, cirrhosis, adrenal insufficiency, use of NSAID/narcotic/thiazide

- Treatment: correction of hypovolemia & anemia / salt replacement (oral/IV)
  fludrocortisone / urea may be tried
## MANAGEMENT OF SPECIFIC PROBLEMS

<table>
<thead>
<tr>
<th>FEATURE</th>
<th>SIADH</th>
<th>CSWS</th>
<th>DI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser. Na</td>
<td>&lt;135 mEq/L</td>
<td>&lt;135 mEq/L</td>
<td>Variable, Elevated</td>
</tr>
<tr>
<td>PLASMA OSM</td>
<td>&lt;280 mOsmol/L</td>
<td>&lt;280 mOsmol/L</td>
<td>Variable, Elevated</td>
</tr>
<tr>
<td>URINE Na</td>
<td>&gt;20 mEq/L</td>
<td>&gt;20 mEq/L</td>
<td>Variable</td>
</tr>
<tr>
<td>URINE OSM</td>
<td>&gt;Plasma osm</td>
<td>&gt;Plasma osm</td>
<td>50-150 mOsm/L</td>
</tr>
<tr>
<td>Ser. K</td>
<td>Low/normal</td>
<td>High/normal</td>
<td>Normal</td>
</tr>
<tr>
<td>BLOOD VOL</td>
<td>Increased</td>
<td>Decreased</td>
<td>Normal/ Decreased</td>
</tr>
<tr>
<td>Na BALANCE</td>
<td>Variable</td>
<td>Negative</td>
<td>High</td>
</tr>
<tr>
<td>BODY Wt</td>
<td>Increased</td>
<td>Decreased</td>
<td>Normal/ Decreased</td>
</tr>
<tr>
<td>CARDIAC FILLING Pr.</td>
<td>Increased/Normal</td>
<td>Decreased</td>
<td>Normal/ Decreased</td>
</tr>
<tr>
<td>HCT</td>
<td>Decreased</td>
<td>Increased</td>
<td>Normal/ Decreased</td>
</tr>
<tr>
<td>BUN : Cr</td>
<td>Decreased / Normal</td>
<td>Increased</td>
<td>Normal/ Decreased</td>
</tr>
<tr>
<td>BP</td>
<td>Normal</td>
<td>Postural hypotension</td>
<td>Normal/ Decreased</td>
</tr>
<tr>
<td>HR</td>
<td>Normal</td>
<td>Tachycardia</td>
<td>Normal/Tachycardia</td>
</tr>
<tr>
<td>OTHER</td>
<td>Normal thyroid+renal function/ no edema/ no dehydration</td>
<td>S/S of volume depletion</td>
<td>UO &gt;3 lit/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>UO&gt; 250 ml/hr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ur Sp Gr &lt;1003</td>
</tr>
</tbody>
</table>
SAH may be a/w cardiac arrhythmia and ECG changes in over 60% cases; may be indistinguishable from acute MI

Possible mechanism: hypothalamic ischemia causes increased sympathetic tone with resultant catecholamine surge producing sub-endocardial ischemia or coronary vasospasm

Stunned myocardium: “reversible post ischemic myocardial dysfunction”. Some patients may develop myocardial hypokinesis following SAH, attributed to defect in Troponin –I. Mimic MI on echo but cardiac enzymes are negative

Hypotension usually does not occur since reduced CO is offset by increased SVR. Reduced CO may impair the ability to tolerate barbiturate and may also impede the use of hyperdynamic therapy for vasospasm
RESPIRATORY COMPLICATIONS:

- Common in poor clinical grade and advanced age
- 50% deaths from medical cause
- MC respiratory complications are pulmonary edema, pneumonia, atelectasis, aspiration, pneumothorax, asthma and pulmonary embolism
- Indication for intubation and controlled respiration include gross abnormality in RR, hypoxia, hypercapnia, depressed consciousness
Pulmonary edema may complicate any moment following SAH & may be cardiogenic/ neurogenic/ 2° to pulmonary insult viz aspiration or shock. Treated by immediate intubation/ ventilation, adequate oxygenation, PEEP, frusemide

Most pneumonia occurs in intubated patients. Prevention include removal of NG & ET tubes as soon as indicated, avoidance of gastric distension, strict hand washing, semi-recumbent positioning, adequate nutrition, use of sucralfate in place of H2 blocker/PPI & proper ventilator care

Use of prophylactic antibiotic is controversial

Tracheostomy and percutaneous feeding gastrostomy
VENOUS THROMBOEMBOLISM:

- 2% of SAH patients develop symptomatic DVT, 50% of them has PE, which is fatal in half
- Asymptomatic DVT occurs in 19-50%
- Graduated compression stockings & pneumatic compression devices decreases incidence of DVT
- Low dose heparin or LMWH usually started only after securing source viz aneurysm
- For diagnosed DVT/PE IVC filters are optimal choice
MANAGEMENT OF SPECIFIC PROBLEMS

GASTRO INTESTINAL COMPLICATION:

- Early nutritional support (oral/NG/PEG/Feeding jejunostomy) to counteract hypercatabolic state

- Stress ulcer and GI bleed: preventive measures (sucralfate/H2 blocker/PPI)

- Stool softeners are administered routinely to prevent straining/impaction/abdominal pain. Nimodipine may be a/w pseudo-obstruction & ileus, usually resolves on conservative measure

- Up to 24% of SAH patients develop increased hepatic enzymes and 4% develops severe liver dysfunction. It may be d/t passive liver congestion, SIRS or drug induced
MANAGEMENT OF SPECIFIC PROBLEMS

REBLEEDING:

- Maximal frequency is in 1st day (4%), then 1.5% daily for 13 days. 15-20% rebleed within 14 days, 50% within 6 months and then 3% per year.

- Risk increases with higher H/H grade, pre op ventriculostomy / lumbar spinal drainage.

- Risk of rebleeding in SAH of unknown origin / AVM / multiple unruptured aneurysm are similar at approx 1% per year.
Prevention of rebleed:

- Early treatment (coiling/surgery). Bed rest do not prevent rebleeding

- Antifibrinolytic therapy – Tranexamic acid reduces the risk of rebleeding. Loading dosage of 1 gm bolus followed by 1 gm q 6 hrs until aneurysm is secured (max 72 hrs)

- Epsilon aminocaproic acid (EACA) – competitively blocks activation of plasminogen to plasmin. Incidence of rebleed is reduced but there is more incidence of HCP/DIND on prolonged use. Because of increased risk of cerebral infraction, its use was discouraged
HYDROCEPHALUS FOLLOWING SAH: acute HCP

- Optimal range of incidence 15-20% after initial CT following SAH
- 30-60% has no impairment of consciousness
- 3% develop delayed HCP within 1 week
- Possible mechanism: CSF outflow obstruction by blood at aqueduct/4th ventricular outlet/subarachnoid space and/or at arachnoid granulation
- Risk factors: senility, intraventricular blood, diffuse subarachnoid blood, HTN, posterior circulation aneurysm, poor sensorium on admission, use of antifibrinolytics
Management of Specific Problems

Treatment of acute HCP:

- Patients in poor grade SAH with large ventricles may be symptomatic from HCP and considered for ventriculostomy, which causes improvement in 80% cases.

- ICP recommended to keep in the range of 15-25 mm Hg and to avoid rapid pressure reduction to decrease the risk of ventriculostomy induced aneurysmal rebleed. After securing the aneurysm ICP should be maintained in the range of 5-10 mm Hg.
MANAGEMENT OF SPECIFIC PROBLEMS

Chronic HCP:
- Reported range is 8-45%
- Chronic HCP is due to pia-arachnoid adhesions or permanent impairment of arachnoid granulations
- Acute HCP does not inevitably lead to chronic HCP
- 50% permanent CSF diversion
- Presence of intraventricular blood during acute stage increases the risk of shunt dependency
- Controversy: use of ventriculostomy in acute HCP increases or possibly decreases incidence of shunt dependency
MANAGEMENT OF SPECIFIC PROBLEMS

CEREBRAL VASOSPASM:

- Usually seen after aneurysmal SAH, but may be seen in IVH from AVM, head trauma, brain surgery, LP, hypothalamic injury, infection, SAH of any etiology and may be a/w pre-eclampsia
MANAGEMENT OF SPECIFIC PROBLEMS

- **CLINICAL VASOSPASM** – delayed ischemic neurological deficit (DIND): a delayed focal ischemic neurologic deficit following SAH, clinically characterized by confusion/deceased level of consciousness with FND (speech/motor)

- **RADIOGRAPHIC VASOSPASM** (angiographic vasospasm) – arterial narrowing demonstrated on cerebral angiography, often with contrast slow filling

- **SYMPTOMATIC VASOSPASM** – when DIND corresponds to a region of vasospasm seen on angiogram
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

Clinical finding of cerebral vasospasm – usually develop gradually, may progress and fluctuate

- Non localizing finding – New or increasing headache
  - Alteration of level of consciousness
  - Disorientation
  - Meningismus

- Focal neurological sign – Cranial nerve palsy
  - Focal neurological deficit
  - Anterior cerebral artery syndrome (mc)
  - Middle cerebral artery syndrome
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

- **ACA syndrome** – frontal lobe findings predominate (abulia, grasp/suck reflex, urinary incontinence, drowsiness, slowness, delayed response, confusion). B/L ACA infarct are usually d/t vasospasm after AComA aneurysm rupture

- **MCA syndrome** – hemiparesis, monoparesis, aphasia, ideomotor apraxia
INCIDENCE:

- Radiographic vasospasm is found in 30-70% of DSA done around 7\textsuperscript{th} day following SAH
- Symptomatic vasospasm occur in 20-30% of patients with SAH
- Radiographic \textit{cerebral vasospasm} (CVS) may occur in absence of clinical deficit, and vice-versa
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

SEVERITY:

- CVS is the most significant cause of morbidity and mortality in patients surviving SAH.
- Ranges from mild reversible dysfunction to severe permanent deficit secondary to ischemic infarction (7%) and may be fatal (7%).
- Earlier onset CVS is a/w greater deficit.
TIME COURSE OF VASOSPASM:

- Onset is almost never before day 3 post SAH
- Max frequency on day 6-8 post SAH
- Clinical CVS usually resolves by day 12 post SAH but radiological CVS is demonstrated, it usually resolves slowly over 3-4 weeks time
- Onset is usually insidious but in 10% may have abrupt and severe deterioration
CORRELATED FINDINGS:

- Blood clots are spasmogenic when in direct contact with proximal 9 cm of ACA and MCA.
- H & H grade on admission correlate with risk of CVS, grade 1 has 22% incidence and grade 3 and above has > 50% incidence of DIND.
- Amount of blood in CT correlate with severity of CVS. Fisher group 1 carries 0-2% risk where as group 3 carries up to 23% risk of DIND.
- Higher incidence found with increasing age, cigarette smoking, preexisting HTN, use antifibrinolytic agents, angiographic dye, hypovolemia.
- Pial enhancement on CECT approx 3 days after SAH may correlate with higher risk of CVS, indicating increased permeability of BBB.
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

PATHOGENESIS:
- Poorly understood
- Degraded products from hemolyzed RBC may be the “spasmogens”
- Theories of CVS –

<table>
<thead>
<tr>
<th>STRUCTURAL THEORY</th>
<th>VASOCONSTRICTION THEORY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proliferative vasculopathy</td>
<td>Free radical lipid peroxidation</td>
</tr>
<tr>
<td>Immune vasculopathy</td>
<td>Derangement in eicosanoid production</td>
</tr>
<tr>
<td>Vessel wall inflammation</td>
<td>Nitric oxide deficit</td>
</tr>
<tr>
<td>Extracellular lattice contraction</td>
<td>Endothelin excess</td>
</tr>
<tr>
<td>--</td>
<td>Neurogenic factors</td>
</tr>
</tbody>
</table>
SAH

RELEASE OF VASOCONSTRICTORS

OXY HB  ENDOTHELIN RELEASE

FREE RADICALS (Fe)  RECEPTORS (ETa,ETb) STIMULATION

LIPID PEROXIDATION  G- PROTEIN ACTIVATION

ACTIVATION OF PHOSPHOLIPASE (C,D,A2)

HYDROLYSIS OF PHOSPHOLIPIDS (PG E2, TxA2, LOW PGI2)

INCREASED CALCIUM  INCREASED DAG

CALPAIN ACTIVATION  →  PROTEOLYSIS  →  PKC ACTIVATION

PROTEIN DEGADATION (CALPONIN, OTHERS)  PROTEIN PHOSPHORYLATION (CALDESMON, OTHERS)

INHIBITORY EFFECT ON ACTOMYOSIN ATPase LOST

CALCIUM INFLUX  INHIBITION OF CA- ATPase

SUSTAINED VASOCONSTRICTION
**MANAGEMENT OF SPECIFIC PROBLEMS** (cerebral vasospasm)

**PATHOLOGY**: ARTERIAL WALL CHANGES AFTER VASOSPASM

<table>
<thead>
<tr>
<th>TIME</th>
<th>VESSEL LAYER</th>
<th>PATHOLOGIC CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1-8</td>
<td>Adventitia</td>
<td>Increased inflammatory cells (L, PC, MC) &amp; connective tissue</td>
</tr>
<tr>
<td></td>
<td>Media</td>
<td>Muscle necrosis and corrugation of elastica</td>
</tr>
<tr>
<td></td>
<td>Intima</td>
<td>Thickening with endothelial swelling and vacuolization, opening of inter-endothelial tight junction</td>
</tr>
<tr>
<td>Day 9-60</td>
<td>Intima</td>
<td>Proliferation of SMC → progressive intimal thickening</td>
</tr>
</tbody>
</table>
MANAGEMENT OF SPECIFIC PROBLEMS  (cerebral vasospasm)

DIAGNOSIS CVS:

- Clinical Criteria – Delayed onset of persistent neuro deficit onset 4-20 days post SAH
deficit appropriate to involved arteries

- R/O other causes of deterioration –
  Rebleeding
  HCP
  Cerebral edema
  Seizure
  Metabolic disturbances viz hyponatremia
  Hypoxia
  Sepsis
Ancillary tests: Trans Cranial Doppler (TCD)

- Introduced by Aaslid & colleague (1980); works on the principle that as an artery narrows, blood flow velocity within it increases
- May precede clinical symptoms by 24-48 hrs

<table>
<thead>
<tr>
<th>Mean MCA velocity</th>
<th>MCA : ICA (Lindegaard Ratio)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 120 cm/sec</td>
<td>&lt; 3</td>
<td>Normal</td>
</tr>
<tr>
<td>120- 200 cm/sec</td>
<td>3-6</td>
<td>Mild vasospasm</td>
</tr>
<tr>
<td>&gt; 200 cm/sec</td>
<td>&gt; 6</td>
<td>Severe vasospasm</td>
</tr>
</tbody>
</table>
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

- CEREBRAL IADSA: vasospasm appear as concentric narrowing which can be focal/segmental/diffuse. Graded as mild (<25%), moderate (25-50%) or severe (>50%)

- MRA / CTA: may be useful, not a practical alternative to DSA

- EEG: decline in percent of Alpha activity (6-14 Hz), called relative alpha (0.45 – 0.17) predicted onset of vasospasm earlier than TCD

- MRI: DWI & PWI may detect early ischemia

- Xenon CT: may detect large global changes in CBF but insensitive to detect focal blood flow changes

- PET / SPECT: non-quantitative and takes longer time
PREVENTION OF CVS:

- Vasospasm can often be mitigated by preventing post SAH hypovolemia & anemia by employing slight over hydration & blood transfusion

- Smooth muscle relaxants:
  - CCB didn’t succeed in counteracting vasospasm but may provide neuro-protectant effect
  - Endothelin receptor antagonist, clazosentan (ETa)

- Direct mechanical arterial dilatation: balloon angioplasty (60-80% clinical improvement)
- Indirect arterial dilatation: utilizing hyperdynamic therapy
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

- Removal of potential vasospasmogenic agents:
  - Removal of blood clot (mechanical removing during surgery / subarachnoid irrigation with thrombolytic agents viz rt-PA at surgery or cisternal catheters or intrathecally)
    
    (Findlay JM et al: RCT of intraoperative, intracisternal TPA for prevention of vasospasm)
  - CSF drainage via serial LP/EVD/post op. cisternal catheter

- Sympatholytics / Cervical sympathectomy
- Intra-arterial or intra-thecal papaverine / verapamil
- Alpha ICAM 1 inhibition (Ab)
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

- Protection of CNS from ischemic injury:
  - CCB
  - NMDA receptor antagonist (selfotel / eliprodil / cerestat)
  - Free radical scavengers (tirilazad mesylate / nicaraven)

- Improvement of rheological properties of intravascular blood to enhance perfusion
  - plasma / albumin / LMW dextran / PFC / mannitol
  - optimal hematocrit is controversial but 30-35% is a good compromise between lowered viscosity without overlay reducing O2 carrying capacity

- Extracranial – intracranial bypass around zone of vasospasm
MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

Promising agents in trial –

- Nicardipine prolonged release implants (NPRIs)
- Clazosentan
- Nizofenone (neuroprotectant, effective in controlled clinical trial)
- High dose methylprednisolone (effective in cohort clinical trial)
- Calcitonin gene related peptide slow release tab IT (effective in primate model)
- Hydroxyl radical scavenger – nicaraven (effective in controlled clinical trial)
- Combination of inotrope & vasodilator drug milrinone (controlled dog study)
- Vasodilator papaverine slow release pellets (effective IT in dog model)
- Neuroprotectant ebselen/simvastatin (effective in controlled clinical trial)
- Pulse dye LASER delivered by endovascular catheter to reverse vasospasm
- Role of intra cisternal papaverine
### MANAGEMENT OF SPECIFIC PROBLEMS (cerebral vasospasm)

### STRATEGIES FOR VASOSPASM PREVENTION:

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoidance of hypovolemia/ hypotension/ antihypertensive/ antifibrinolytics / raised ICP</td>
<td>Prevent ischemia</td>
</tr>
<tr>
<td>Subarachnoid clot removal or lysis with fibrinolytic agents</td>
<td>Prevent vasospasm</td>
</tr>
<tr>
<td>CCB or other potential calcium based neuro-protectant</td>
<td>Prevent ischemic damage (?)</td>
</tr>
<tr>
<td>21- aminosteroid &amp; other antioxidant, lipid peroxidation inhibitor, free radical scavenger</td>
<td>Prevent ischemic damage (?)</td>
</tr>
<tr>
<td>Intra-thecal slow release vasodilator</td>
<td>Prevent vasospasm (experimental)</td>
</tr>
<tr>
<td>Endothelin inhibitor and antagonist</td>
<td>Prevent vasospasm (experimental)</td>
</tr>
</tbody>
</table>
STRATEGIES FOR VASOSPASM REVERSAL:

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypervolemia, hemodilution and hypertension</td>
<td>Reverses ischemia</td>
</tr>
<tr>
<td>Intra-arterial papaverine administration</td>
<td>Reverses vasospasm</td>
</tr>
<tr>
<td>Percutaneous transluminal balloon angioplasty (PTBA)</td>
<td>Reverses vasospasm</td>
</tr>
<tr>
<td>Intraventricular nitroprusside</td>
<td>Reverses vasospasm (experimental)</td>
</tr>
<tr>
<td>Intra aortic balloon counterpulsation (for concomitant heart failure)</td>
<td>Reverses vasospasm along With PTBA</td>
</tr>
</tbody>
</table>
## CVS MANAGEMENT PROTOCOL: (post clipping)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Management</th>
</tr>
</thead>
</table>
| **No vasospasm**  
  - clinically intact  
  - normal TCD | 1. Hemodynamics: normotension, keep SBP > 120 mm Hg  
  2. IVF: NS 200 ml/hr |
| **Subclinical vasospasm**  
  - high TCD (> 200 cm/sec)  
  - radiographic vasospasm  
  - clinically intact | 1. Monitors: PA catheter, A-line  
  2. Elderly & pt. with CAD: ECG, cardiac echo, cardiac enzymes to assess left ventricular function  
  3. Monitor for S/S of a/e of 3-H therapy (chest pain, pulmonary rhonchi, ECG changes)  
  4. Hemodynamics: maintain SBP 160-220 mm Hg (may add DA/NorAd/Dobutamine), maintain PCWP 12-14 mm Hg  
  5. Hematocrit: to maintain < 33%  
    - IVF = NS + plasma 200-250 ml/hr, ½ NS if Na>150 meq/L  
    - DDAVP if UO > 200 ml/hr X 4 hrs |
| **Clinical vasospasm**  
  - DIND  
  - high TCD (> 200 cm/sec)  
  - radiographic vasospasm | 1. Increase SBP 200-220 mm Hg  
  2. Increase PCWP to 18-21 mm Hg (CXR- to r/o pulmonary edema) / CVP 8-12 cm H2O  
  3. Refractory case: angioplasty, IA verapamil |
### TRIPLE “H” THERAPY

| **HYPERTENSION** | 1. Dopamine: start at 2.5 mcg/kg/min and titrate up to 15-20 mcg/kg/min  
|                  | 2. Dobutamine: start at 5 mcg/min titrate to 20 mcg/kg/min  
|                  | 3. Phenylephrine: start at 5 mcg/min titrate up to 10 mcg/kg  
|                  | 4. Norepinephrine: start at 1-2 mcg/min & then increase by 10 mcg/min |

| **HYPERVOLEMIA** | 1. IVF: NS @ 200 - 250 ml/hr  
|                  | 2. Albumin / plasma  
|                  | 3. DDAVP: antidiuretic, 2-4 mcg SQ q D in divided doses |

| **HEMODILUTION** | 1. Target hematocrit: < 33%  
|                  | 2. Blood transfusion for Hct < 25% |
Complication of hyperdynamic therapy:

- **Intra cranial** – cerebral edema
  - raised ICP
  - hemorrhagic infarction in the area of ischemia

- **Extra cranial** – pulmonary edema (17%)
  - cardiac failure
  - dilutional hyponatremia (3%)
  - MI (2%)

- **Complication related to catheter** –
  - catheter related sepsis (13%)
  - subclavian vein thrombosis (1.3%)
  - pneumothorax (1%)
  - hemothorax
EARLY ANEURYSM REPAIR

DIND

H/O CCF or IHD

PA CATHETER OR DIRECT BALLOON ANGIOPLASTY

HCT 35%, Hb >10
Hypervolemia (CVP 8-10, PCWP 14-16)
Inotropic infusion (DA / Dobutamine)

CLINICAL RESPONSE

No clinical &/or BP response in 1 hr

Phenylephrine or NorAd

BP > 200 mm Hg
NO CLINICAL RESPONSE IN 1 HR

CT to r/o Infarction

BALLOON ANGIOPLASTY
MANAGEMENT OF SPECIFIC PROBLEMS

MISCELLANEOUS COMPLICATIONS FOLLOWING SAH:

- Fever and SIRS
- Genito-urinary: cystitis/renal failure
- Metabolic: hyperglycemia/hypercatabolic state
- Hematological: anemia
- Poor immunity
SAH IN PREGNANCY

- Intracranial hemorrhage of pregnancy (ICHOP) commonly occurs in the setting of eclampsia, MC being intra-parenchymal bleed

- ICHOP- related SAH revealed 77% were aneurysmal, 22% from ruptured AVM

- Increasing tendency for bleeding with advancing gestational age for both aneurysm & AVM

- CT/ DSA scan with shielding of fetus, well hydration of mother to diminish s/e of contrast
SAH IN PREGNANCY

Management modification:

- Mannitol should be avoided to prevent fetal dehydration maternal hypovolemia with uterine hypoperfusion

- Seizure prophylaxis – carbamazepine / valproate with lowest dose is the preferred AED

- Nitroprusside should not be used

- Nimodipine is potentially teratogenic in animals, should be used only when potential benefit justify the risk

- C.S. may be used for fetal salvage for moribund mother in 3rd trimester
Thank you